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ABSTRACT  
 
Background: Mutations in BRCA1 and BCRA2 (BRCA1/2), components of the 
homologous recombination DNA repair (HRR) pathway, are associated with 
hereditary breast and ovarian cancers. Poly(ADP-ribose) polymerase (PARP) 
inhibitors are selectively cytotoxic to animal cells with defective HRR but 
results in human cancer cells have been contradictory. We undertook, to our 
knowledge, the first comprehensive in vitro and in vivo investigations of the 
antitumor activity of the PARP inhibitor AG014699 in human cancer cells 
carrying mutated or epigenetically silenced BRCA1/2.  
Methods: We used nine human cell lines: four with non-mutated BRCA1/2 (MCF7, 
MDA-MB-231, and HCC1937-BRCA1 [breast cancer] and OSEC-2 [ovarian 
surface epithelial]), two with mutated BRCA1 (MDA-MB-436 and HCC1937 
[breast cancer]), one with mutated BRCA2 (CAPAN-1 [pancreatic cancer]), 
one that was heterozygous for BRCA2 (OSEC-1 [ovarian surface epithelial]), 
and one with epigenetically silenced BRCA1 (UACC3199 [breast cancer]) and 
two Chinese hamster ovary cell lines, parental AA8 and XRCC3 mutated IRS 
1SF. We assessed cytotoxicity, DNA damage, and HRR function. Antitumor 
activity of AG014699 was determined by growth of xenograft tumors (five 
mice per treatment group). Long-term safety of AG014699 was assessed.  
Results: AG014699 (≤10 μM) was cytotoxic to cells with mutated BRCA1/2 or 
XRCC3 and to UACC3199 cells with epigenetically silenced BRCA1 but not to 
cells without BRCA1/2 or XRCC3 mutations or that were heterozygous for 
BRCA2 mutation. AG014699 induced DNA double strand breaks in all nine 
cell lines studied. HRR was observed only in cells with functional BRCA1/2 
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proteins. Growth of xenograft tumors with BRCA1/2 mutations or with 
epigenetically silenced BRCA1 was reduced by AG014699 treatment, and 
combination treatment with AG014699 plus carboplatin was more effective 
than either drug alone. AG014699 was not toxic in mice with non-mutated or 
heterozygous BRCA2.  
Conclusions: Human cancer cells or xenograft tumors with mutated or 
epigenetically silenced BRCA1/2 were sensitive to AG014699 monotherapy, 
indicating a potential role for PARP inhibitors in sporadic human cancers.  
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INTRODUCTION 
 
Mutations in BRCA1 and BRCA2 genes are associated with a high life-time 
risk of breast and ovarian cancer (1-2). BRCA1 and BRCA2 proteins play a major 
role in the response to and repair of DNA double-strand breaks through the 
homologous recombination repair (HRR) pathway (3). HRR, a complex error-free 
process, repairs double-strand break occurring in late S and/or G2 phase of the cell 
cycle and stalled replication forks after unrepaired single-strand breaks. In HRR-
defective, BRCA1 and/or BRCA2 (BRCA1/2)-mutated cells, failure to execute error-
free repair can result in the chromosomal aberrations and genomic instability 
characteristic of tumors (3). Preclinical studies (4, 5) have reported that cells with 
mutated BRCA1/2 genes are sensitive to poly(ADP-ribose) polymerase (PARP) 
inhibitors. PARP-1 and PARP-2 are abundant nuclear proteins that form poly(ADP-
ribose) (PAR) chains in response to DNA damage. They play a crucial role in DNA 
single-strand break repair (6). PARP inhibition leads to accumulation of single-strand 
breaks that during replication are converted to double-strand breaks, which are 
normally repaired by the HRR pathway (7). In HRR-defective cells with BRCA1/2 
mutations, PARP inhibitors are synthetically lethal by inactivating the single-strand 
break repair pathway through inhibition of PARP-1 and/or -2 and the subsequent 
accumulation of irreparable double-strand breaks (8). Synthetic lethality, defined as 
the lethal effect of inactivating two enzymes or pathways when inactivation of either 
alone is tolerated, has major potential for cancer therapy. 
Cells that lack other components of the HRR pathway or in which such 
components have been experimentally depleted (eg, RAD51, RAD54, ATR, or 
XRCC3 protein) have also been shown to be sensitive to PARP inhibitors (4, 9), 
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indicating that sensitivity may require defective homologous recombination in 
general, not just BRCA1/2 mutations. Moreover, epigenetic gene inactivation by 
promoter CpG island methylation is a well-recognized mechanism for silencing tumor 
suppressor genes (10) and BRCA1 methylation has been reported in approximately 
15% of sporadic breast and ovarian cancers (11-12). Dysfunction of BRCA1 is also a 
feature of basal-like, triple-negative breast cancers, which are phenotypically similar 
to BRCA1-associated breast cancers (ie, tumors that are estrogen receptor negative, 
have a high nuclear grade and high Ki-67 staining, and express cytokeratin 5/6 and 
epidermal growth factor receptor) (13, 14). In addition, over-expression of EMSY 
mRNA, which represses BRCA2 protein function, has been observed in 13% of 
sporadic breast cancers and 17% of high-grade sporadic ovarian cancers 
(15).Therefore, a substantial proportion of sporadic breast and ovarian cancers may 
have defective HRR and thus be sensitive to PARP inhibitors (16). 
In contrast to results from studies with non-cancerous genetically naïve 
BRCA1/2-negative embryonic stem cells, BRCA2-deficient Chinese hamster lung 
fibroblasts, or genetically modified human cell lines, results from studies examining 
the sensitivity of human cancer cell lines to PARP inhibitors have been negative. De 
Soto et al. (17) found that human BRCA1-positive, BRCA1 heterozygous, and 
BRCA1-negative breast cancer cell lines were not sensitive to three different PARP 
inhibitors (ie, 3-aminobenzamide, NU1025, and AG14361). In addition, Gallmeier et 
al. (18) found that BRCA2-defective human pancreatic cancer CAPAN-1 cells were 
not sensitive to the PARP inhibitor NU1025. In view of these conflicting preclinical 
data, we undertook, to our knowledge, the first comprehensive study of the 
therapeutic potential of AG014699 in a panel of nine human cell lines with proficient 
or deficient HRR. 
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We investigated the cytotoxicity of the PARP inhibitor, AG014699, by colony 
formation and sulforhodamine B assays, the mechanism of AG014699 cytotoxicity by 
DNA damage and repair immunofluoresence assays, the safety of AG014699 in mice 
that were heterozygous for BRCA2 after six cycles of AG014699 treatment and 12 
months of follow-up, and the antitumor activity of AG014699 by measuring growth of 
MDA-MB-436, CAPAN-1, and UACC3199 xenograft tumors in mice.  
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MATERIALS AND METHODS 
 
Reagents  
 
AG014699 was provided by Pfizer GRD (La Jolla, CA) and is a potent 
inhibitor of PARP-1 and PARP-2 proteins (with an inhibition constant of <5 nM). 
AG014699 was dissolved in dimethyl sulfoxide to give a stock solution of 10 mM 
AG014699, which was stored at –200C for in vitro studies. For in vivo experiments, 
AG014699 was dissolved in water at 1 mg/mL. All other chemicals and tissue culture 
reagents were from Sigma, unless otherwise stated. 
 
Cell Lines  
 
CAPAN-1 cells are human pancreatic cancer cells with mutated BRCA2 (ie, 
6174delT) in one allele and loss (or deletion) of the other allele (ie, loss of 
heterozygosity) (19). We used the following five human breast cancer cell lines, 
which we obtained from the American Type Culture Collection (Manassas, Virginia, 
USA): MCF7 cells carry non-mutated BRCA1/2; MDA-MB-231 cells are hemizygous 
in BRCA1, with loss of one allele and the remaining non-mutated allele containing 
two nonpathogenic single-nucleotide polymorphisms; MDA-MB-436 cells carry 
mutated BRCA1 (5396 +1G>A in the splice donor site of exon 20) (20, 21); HCC1937 
cells carry mutated BRCA1 (5382insC) (22); and HCC1937-BRCA1 cells were 
derived from HCC1937 by correcting the BRCA1 mutation (23). UACC3199, a human 
breast cancer cell line, has BRCA1 genes that have been silenced by methylation 
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(24); the identity of these cells was confirmed by Valerie Deregowski (University of 
Leven) by methylation specific polymerase chain reaction. UACC3199 cells were 
purchased from the University of Arizona Cancer Research Center, Tucson. We used 
the following two immortalized human ovarian surface epithelial cells: OSEC1 cells 
are heterozygous for BRCA2 (ie, with 4630insA in exon 11 as one allele and 
nonmutated BRCA2 as the other allele; R. J. Edmondson, unpublished data); OSEC2 
cells carry non-mutated BRCA1/2 (25). The following two Chinese hamster ovary cell 
lines were used: XRCC3-deficient IRS 1SF cells and for comparison AA8 cells with 
wild-type XRCC3. XRCC3-deficient IRS 1SF cells are established models for 
homologous recombination dysfunction (26) and were provided by Prof Penny Jeggo 
(Sussex University, Brighton, UK). Early passages (<30) of all cell lines were 
maintained in exponential growth at 370C in a humidified atmosphere of 5% CO2 and 
95% air. All cells were handled separately with their own unique reagents and were 
confirmed to be mycoplasma-free by regular testing (MycoAlert Mycoplasma 
detection kit, Lonza, Rockland, Maine). MCF7, MDA-MB-231, OSEC1, OSEC2, 
UACC3199, HCC1937, HCC1937-BRCA1, AA8, and IRS-1SF cells were maintained 
in RPMI 1640 medium supplemented with 10% fetal bovine serum, penicillin (100 
units/mL), and streptomycin (1.0 mg/mL). CAPAN-1 cells were cultured as above but 
supplemented with 15% fetal bovine serum. MDA-MB-436 cells were cultured in 
RPMI 1640–Leibovitz medium (50:50 vol/vol), 4 mM L-glutamine, 10% fetal bovine 
serum, penicillin (100 units/mL), and streptomycin (1.0 mg/mL). All cell lines, 
described above, were used in all in vitro assays, unless otherwise indicated.  
 
Clonogenic Assay for Cell Survival  
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All human cell lines (except the HCC1937 and HCC1937-BRCA1) and both 
Chinese hamster ovary cell lines were used for this assay. Exponentially proliferating 
cells were plated into six-well plates and incubated for 48 hours to allow cells to 
reach their optimum proliferation rate. AG014699 at 0, 0.1, 1.0, 10.0, 30.0, 50.0, or 
100 μM in 1% dimethyl sulfoxide was added to the wells and incubated for 24 hours. 
Control cells received no AG014699 but were treated with medium containing 1% 
dimethyl sulfoxide for 24 hours. Cells were harvested and cultured in drug-free 
medium in 90-mm Petri dishes for up to 21 days, depending on the proliferation rate 
of the individual cell line. Colonies were fixed in methanol and acetic acid (3:1 
vol/vol), stained with methyl violet 10B, and counted with an automated colony 
counter (Oxford Optronix, Oxford, UK). Data are expressed as the percentage of 
colonies in AG014699-treated cultures compared with that in control cultures. The 
concentration that results in death of 50% of cell population (LC50) was calculated for 
each cell line in each independent experiment. Each assay contained triplicate 
samples for each concentration. Results represent data from at least three 
independent experiments. 
 
Sulforhodamine B Assay for Cell Growth Inhibition  
 
We used the following breast cancer cell lines for this assay: HCC1937, 
HCC1937-BRCA1, and MDA-MB-231. The HCC1937 and HCC1937-BRCA1 cell 
lines have poor cloning efficiency and thus are not appropriate for the clonogenic cell 
survival assay. As an alternative, we measured cell growth with the sulforhodamine B 
protein dye assay (27). MDA-MB-231 cells were also evaluated with this assay so 
that a direct comparison could be made between results from the clonogenic survival 
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assay and the sulforhodamine B assay. Briefly, cells were seeded into 96-well plates 
at 2000 cells per well and allowed to attach overnight. AG014699 at 0.0, 1.0, 10.0, 
30.0, 50.0, or 100 μM in 1% dimethyl sulfoxide was added, and cells were incubated 
for 140 hours at 37°C, fixed in 50% (wt/vol) trichloroacetic acid, and stained with 
0.4% sulforhodamine B solution (diluted in 1% acetic acid) for 30 minutes. 
Absorbance of sulforhodamine B was measured at 520 nm with a SpectroMax 250 
microplate spectrophotometer system (MDS Analytical Technologies, Toronto, 
Canada) to determine cell density. The concentration required to produce 50% 
inhibition of cell growth (GI 50) was calculated for each cell line in each independent 
experiment. Each assay contained triplicate samples for each concentration. Results 
represent data from at least three independent experiments.  
 
Assay for PARP Activity  
 
We determined PARP activity after AG014699 treatment with the validated 
assay as used in the phase I clinical trial of AG014699 (28). Briefly, cells were 
incubated in medium containing 10 µM AG014699 and 1% dimethyl sulfoxide or 1% 
dimethyl sulfoxide (control) for 30 minutes at 37 0C. Medium was removed and cells 
were washed in phosphate-buffered saline (PBS) before use in this assay. The assay 
measured the amount of poly(ADP-ribose) synthesized by maximally stimulated 
PARP enzymes during a 6-minute reaction. Briefly, cells were permeabilized with 
digitonin (0.15 mg/mL) and subsequently exposed to blunt-ended oligonucleotide (5’-
CGGAATTCCG-3’; Invitrogen, Paisley, UK) at 200 µg/mL in the presence of excess 
NAD+ (7 mM) in reaction buffer (100 mM Tris-HCl, 120 mM MgCl2, pH = 7.8) for 6 
minutes at 27oC. PAR was detected with the mouse monoclonal anti-PAR 10H 
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antibody (1.5 mg/mL, a gift from Professor Alex Bürkle, University Konstanz, 
Konstanz, Germany). , and the anti-PAR antibody was detected with horseradish 
peroxidase-conjugated polyclonal goat anti-mouse IgG antibody (DAKO). Both 
antibodies were diluted 1:1000 in PBS with 0.05% Tween 20 and 5% milk power). 
Secondary antibody was followed by Amersham ECL detection fluid (GE Healthcare 
Life Sciences, Buckinghamshire, UK) development and chemiluminesence detection 
by the Fujifilm LAS 3000 imager. PARP activity in drug-treated cells was expressed 
as the percentage of the activity in un-treated control cells. Each cell line was 
assayed in triplicate, and results represent data from three independent experiments. 
 
Assay of DNA Double-Strand Breaks  
 
We used the phosphorylated histone H2AX (γH2AX) focus formation assay to 
measure DNA double-strand breaks. Within 1-3 minutes of the formation of a double-
strand break, serine-139 in the unique carboxyl-terminal tail of histone H2AX is 
phosphorylated to generate γH2AX. Several γH2AX histone molecules then localize 
to the site of a double-strand break to form a focus; one focus corresponds to one 
double-strand break within the cell nucleus (29). Cells were cultured on glass 
coverslips and then exposed to medium containing no drug (vehicle control; ie, 1% 
dimethyl sulfoxide) or to 10 μM AG014699 in 1% dimethyl sulfoxide for 24 hours at 
37oC before fixation in ice-cold 100% methanol for 5 minutes. As a positive control 
for DNA damage, cells were cultured on coverslips and then exposed to 2 Gy (2.5 
Gy/minute at 310 kV and 10 mA) of x-ray irradiation from the Gulmay Medical RS320 
irradiation system (Gulmay Medical Limited, Surrey, UK); after this exposure, cells 
were incubated for 30 minutes in culture medium at 37oC to allow focus formation 
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and then fixed as described above. Fixed control, AG014699-treated, or irradiated 
cells were blocked for 1 hour at room temperature in KCM buffer (120 mM KCl, 20 
mM NaCl, 10 mM Tris-HCl at pH 8.0, 1 mM EDTA, 0.1% Triton X-100, 2% bovine 
serum albumin, and 10% milk powder) and then incubated overnight at 40C in 
primary anti-γH2AX histone IgG mouse monoclonal antibody (Upstate). Cells were 
next incubated with secondary Alexa Fluor 546-conjugated goat anti-mouse IgG 
fluorescent antibody (Invitrogen) for 1 hour at room temperature but protected from 
light.  Images of γH2AX foci were obtained with a Leica DMR microscope, RT SE6 
Slider camera, and Advanced Spot software version 3.408 (Diagnostic Instruments 
Inc, Sterling Heights, Michigan). γH2AX foci were counted in 30 nuclei from three 
different areas of each treatment slide. The number of γH2AX foci in treated cells 
was normalized to that in the corresponding un-treated control cells, and results are 
expressed as the percentage of foci in untreated control cells. Three slides were 
prepared for each treatment, and three independent experiments were performed. 
 
RAD51 Focus Formation Assay for Functional HRR  
 
Nuclear RAD51 foci formation can be used as marker of functional HRR as 
localization of the RAD51 recombinase at DNA double strand breaks is an essential 
component of HRR (30, 31). After DNA double-strand break resection, RAD51 binds 
to the resulting overhanging single-stranded DNA to create the nucleoprotein filament 
which can be detected as RAD51 foci by immunofluorescence microscopy. To 
quantify RAD51 foci, cells were cultured on glass coverslips and then exposed to 
medium containing no drug (vehicle control; ie, 1% dimethyl sulfoxide) or to 10 μM 
AG014699 in 1% dimethyl sulfoxide for 24 hours at 37oC. Cells were fixed as 
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described above and incubated overnight at 40C with primary anti-RAD51 rabbit 
polyclonal antibody (Calbiochem), followed by incubation in the dark for 2 hours at 
room temperature with secondary Alexa Fluor 488-conjugated goat anti-rabbit IgG 
antibody (Invitrogen). Cells were imaged and the number of RAD51 foci counted and 
normalized to untreated controls as described above. Three slides were prepared for 
each treatment, and three independent experiments were performed.  
 
Characteristics of the Mice 
CD-1 nude mice (female and aged 10-12 weeks) from Charles River 
laboratories (Wilmington, Massachusetts) were used in all xenograft experiments. 
These mice were maintained and handled in isolators under specific pathogen-free 
conditions, with five mice per cage and 20 cages per isolator. Wild-type 
129/C57BL6/DBA mice and 129/C57BL6/DBA mice (female and aged 10-12 weeks) 
that were genetically engineered to carry a heterozygous BRCA2 mutation (leading 
to a truncated non-functional protein) (32), a gift from Professor Alan Ashworth 
(Institute of Cancer Research, London), were used in the AG014699 toxicity 
experiments. These mice were maintained and handled in standard cages, with five 
mice per cage. All experiments involving mice were reviewed and approved by the 
relevant institutional animal welfare committee and then performed according to the 
UK Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the 
Welfare of Animals in Experimental Neoplasia and UK law. For these experiments, 
mice were treated with drug or control vehicle between the hours of 09.00 and 11.00. 
Treatments were administered intraperitoneally in the animal’s home cage within the 
animal facility. Mice were killed by cervical dislocation for the following reasons: 
tumor size was greater than 10 mm X 10 mm, weight loss was more than 15% of 
baseline, or the study ended as defined a priori  
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Assessment of AG014699 Toxicity in BRCA2 Wild-Type Mice and in BRCA2 
Heterozygous Mutant Mice  
 
Women who carry a mutation in BRCA2 have a high lifetime risk of 
developing breast and /or ovarian cancer. PARP inhibitors represent a novel 
treatment for these cancers; however, concerns about toxicity of these drugs in these 
patient populations remain. To investigate whether long-term administration of 
AG014699 had adverse side effects, we used mice that were heterozygous for 
BRCA2, a genotype that is similar to that of women who carry a mutated BRCA2 
gene. A total of 34 mice were used in this experiment, including 20 BRCA2 
heterozygous mice and 14 of the corresponding wild-type mice. Ten BRCA2 
heterozygous mice and seven wild-type mice received AG014699 (25 mg/kg) 
intraperitoneally once daily on days 1-5 of a 21-day cycle for six cycles, and control 
groups (10 BRCA2 heterozygous mice and seven wild-type mice) received control 
saline (10 mL/kg) intraperitoneally once daily on days 1-5 of a 21-day cycle for six 
cycles. Mice were weighed and their general health was observed daily during the six 
treatment cycles; then three times per week until mice were killed, for reasons 
described above, during the post treatment follow-up period of 1 year. A postmortem 
examination was carried out on each mouse at the time of its death, including a gross 
examination of the vital organs.  
 
Efficacy of AG014699 in Xenograft Models of Tumors by BRCA1/2 Status 
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MDA-MB-436, CAPAN-1, and UAC3199 xenografts in CD-1 nude mice were 
used to test the efficacy of AG014699 because these models represent BRCA1-
mutated, BRCA2-mutated, and BRCA1-silenced tumors, respectively. We 
subcutaneously injected 1 x 107 exponentially growing MDA-MB-436 (BRCA1 
mutated), CAPAN-1 (BRCA2 mutated), or UACC3199 (BRCA1 silenced) cells in 50 
mL of PBS into one site on the right flank of each mouse. When sufficient mice (to 
allow five mice per treatment group) had palpable tumors (ie, ³5 mm x 5 mm), the 
mice were randomly assigned, to avoid treatment bias, to treatment groups (five mice 
per group). All treatments were administered intraperitoneally. Investigators were not 
blinded to the treatment groups. 
 
UACC3199 xenograft tumors. Treatments for mice bearing UACC3199 
xenograft tumors in experiment 1 were as follows: AG014699 (25 mg/kg) 
administered once daily for 10 days or a single dose of carboplatin (75 mg/kg) 
administered on day 1, control mice received saline (10 mL/kg) administered once 
daily for 10 days. Treatment groups in experiment 2 were as follows: AG014699 (10 
mg/kg) administered once daily for 5 days of a 7-day cycle for six cycles or, a single 
dose of carboplatin (75 mg/kg), control mice received saline (10 mL/kg) administered 
once daily for 5 days of a 7-day cycle for six cycles. . 
MDA-MB-436 xenograft tumors. Treatment groups were as follows: Control 
saline (10 mL/kg) once daily for 5 days of a 7-day cycle for six cycles or AG014699 
(10 mg/kg) once daily for 5 days of a 7-day cycle for six cycles or a single dose of 
carboplatin (75 mg/kg) on day 1. 
CAPAN-1 xenograft tumors. Treatment groups were as follows: Saline 
control (10 mL/kg) daily for 10 days, AG014699 (10 mg/kg) once a day for 10 days, 
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AG014699 (10 mg/kg) once daily for 5 days of a 7-day cycle for six cycles, a single 
dose of carboplatin (75 mg/kg) on day 1, a combination of carboplatin (75 mg/kg) on 
day 1 in combination with AG014699 (10 mg/kg) once a day for 10 days, or a 
combination of carboplatin (75 mg/kg) on day 1 with AG014699 (10 mg/kg) once a 
day for 5 days of a 7-day cycle for six cycles  
 Mice were weighed and tumor volumes were determined daily from two-
dimensional caliper measurements and the equation a2 x b/2 (where a = width and b 
= length of the tumor). Tumor data are presented as the dimension-less parameter, 
relative tumor volume (RTV). For example, RTV1 is the tumor volume on the first day 
of treatment (day 0), RTV3 is 3 times larger than RTV1, RTV4 is 4 times larger than 
RTV1, and RTV5 is 5 times that of RTV1.  
 
Statistical Analysis 
 
In vitro cell line data were analyzed by two-tailed Students t tests. In vivo 
tumors data were analyzed by comparing the time taken to reach a specified RTV 
among groups randomly assigned to different treatments with a Mann–Whitney test 
and Minitab software, version 15 (Coventry, UK). All statistical tests were considered 
statistically significant if the P value was less than .05. Statistical tests were two-
sided.  
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RESULTS 
 
PARP Activity in Cells After Exposure to AG014699 
 
We investigated whether AG014699 could inhibit PARP activity in all nine 
human cell lines and both Chinese hamster ovary cell lines by use of a validated 
PARP activity assay (26). In all cell lines studies, a 30-minute exposure to 10 μM 
AG014699 caused greater than 94% inhibition of PARP activity, compared with un-
treated controls (Supplementary Figure 1, available online), demonstrating that 
AG014699 freely permeated the cells and bound to and inactivated PARP and that 
the inhibition persisted during cell permeabilization and subsequent PARP enzyme 
stimulation. There was no statistically significant difference in PARP inhibition across 
cell lines. 
 
Clonogenic Cell Survival and Growth Inhibition Assays to Determine 
Sensitivity of Cell Lines to AG014699  
 
The impact of AG014699 on survival and/or cell growth was determined in all 
cell lines. Using clonogenic cell survival assays, we found that AG014699 was more 
cytotoxic to all cell lines examined with mutations in BRCA1/2 (CAPAN-1 and MDA-
MB-436 cells) or XRCC3 (IRS-1SF cells) than to those with functional HRR (AA8, 
MCF7, MDA-MB-231, and OSEC2 cells) (Figure 1A). Table 1 presents the mean 
LC50 data for all cell lines demonstrating a marked difference in the range for the 
HRR functional cell lines (range of LC50 values = 20.2 – 50.7 µM) and the HRR 
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mutated cells (range of LC50 values = 1.3 – 5.5 µM). The sensitivity of the 
epigenetically silenced BRCA1 UACC3199 cells (mean LC50 = 7.6, 95% CI = 6.1 to 
9.1), was closer to that of the HRR mutant cells than to the cells with functional HRR. 
In contrast, the sensitivity of BRCA2 heterozygous OSEC-1 cells to AG014699 
(mean LC50 = 44.8, 95% CI = 9.3 to 80.3) was within the range of the LC50 results 
observed in the cells with non-mutated BRCA1/2 (Table 1). 
Because of the poor cloning efficiency of HCC1937 and HCC1937-BRCA1 
cells, sulforhodamine B assays were used to determine growth inhibition in response 
to AG014699. We found that BRCA1-defective HCC1937 cells (mean GI50 = 10.51 
μM, 95% CI = 8.80 to 12.22 μM) were more sensitive to AG014699 than HCC1937-
BRCA1 cells (mean GI50 = 16.65 μM, 95% CI = 14.00 to 19.30 μM) and BRCA1 
heterozygous MDA-MB-231 cells (mean GI50 = 16.49 μM, 95% CI = 14.75 to 18.23 
μM) (Figure 1B).  
The sensitivity of cells to 10 μM AG014699 appeared to discriminate between 
cells with a functional HRR system and cells with a dysfunctional HRR system. Thus, 
we used 10 μM AG014699 in subsequent in vitro experiments. 
 
Induction of DNA Double-Strand Breaks After Exposure to AG014699 
 
We investigated whether AG014699 induced DNA double-strand breaks by 
use of a γH2AX focus formation assay. After a 24-hour treatment, we found an 
increased level of gH2AX foci in all 11 cell lines treated with 10 µM AG014699 
compared with that in un-treated control cells (Figure 2A). Variation in the levels of 
gH2AX foci between cell lines was unlikely to be the result of their HRR status 
because similar levels were found in parental BRCA1-mutated HCC1937 and in 
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BRCA1-corrected HCC1937–BRCA1 cell lines. In individual cell lines, levels of 
gH2AX foci after AG014699 treatment were similar to those resulting from exposure 
to 2 Gy of ionizing radiation. Differences in gH2AX focus number could be secondary 
to differences in DNA content, S-phase cell fraction, and cell-number doubling times 
between individual cell lines.  
 
RAD51 Focus Formation and Exposure to AG014699 
 
A 24-hour exposure to 10 µM AG014699 caused a statistically significant 
increase in the number of RAD51 foci for all cell lines examined with functional HRR 
(MCF7, MDA-MB-231, OSEC-2, AA8, and HCC1937-BRCA1 cells) and in a cell line 
that is heterozygous for BRCA2 (OSEC1 cells) compared with the corresponding 
untreated control cells (P <.02). In contrast, AG014699, exposure did not result in a 
statistically significant increase in the number of RAD51 foci in BRCA1/2-mutated 
MBA-MB-436, CAPAN-1 and HCC1937 cells, epigenetically silenced UACC3199 
cells, or XRCC3-mutated IRS-1SF cells compared with corresponding untreated 
controls (Figure 2B). 
  
Toxicity of AG014699 in BRCA2 Heterozygous and Wild-type Mice 
 
We used in vivo experiments to investigate whether AG014699 is non-toxic to 
BRCA2 heterozygous mice. With a follow-up of 365 days, no difference was 
observed in mean body weight or survival between BRCA2 heterozygous and control 
treated groups (Figure 3 A and B). Ten heterozygous and 10 wild-type mice were 
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each treated with a total AG014699 dose of 750 mg/kg. Postmortem examination 
revealed no abnormalities in the major organs of any mouse, except that a BRCA2 
heterozygous mouse treated with AG014699 at 25 mg/kg (aged 426 days) had 
multiple tumors in its liver. One BRCA2 heterozygous mouse treated with AG014699 
at 25 mg/kg (aged 473 days) died of an ear infection. In addition, two wild-type mice 
treated with AG014699 at 25 mg/kg (aged 407 and 445 days), a control wild-type 
mouse (aged 341 days), and a control heterozygous mouse (aged 272 days) died of 
unknown causes.  
 
AG014699 Treatment of Mice Bearing Xenograft Tumors with Epigenetically 
Silenced or Mutated BRCA1 or BRCA2 
 
Epigenetically silenced BRCA1 UACC3199 xenograft tumors. Of the 30 
mice implanted with epigenetically silenced BRCA1 UACC3199 cells, only 15 
developed tumors by 40 days after implantation. These 15 mice were then randomly 
assigned to the following treatment groups (5 mice per group): AG014699 (25 mg/kg 
daily for 10 days), carboplatin (single dose of 75 mg/kg), or saline control. 
UACC3199 tumors grew relatively slowly, with the size of control tumors being an 
RTV of 2.6 at day 10 (Figure 4A and Table 2). Because of the variable lag time for 
tumor appearance (range = 21-32 days), there was up to six-fold variation in tumor 
size (range = 36–214 mm3) when treatment was initiated. In addition, at day 12, two 
mice or more in each group had to be killed because their tumor was larger than 10 
mm x 10 mm. For this reason, data up to and including day 12 are presented (with 
individual tumor measurements being presented in Supplementary Figure 2, 
available online). During the 10-day dosing period, AG014699 at 25 mg/kg appeared 
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to arrest tumor growth, and the RTV in treated groups was less than that in the 
corresponding untreated control mice (RTV = 1.5 on day 10 in AG014699-treated 
mice vs RTV = 2.6 in control mice; difference in RTV = 1.1, P = .04). However, when 
AG014699 treatment stopped, tumors began to grow again. In contrast, the response 
to carboplatin (single dose on day 1) appeared to be delayed, with a slowing of tumor 
growth that was detectable only after day 9 (RTV on day 10 = 1.7).  
Because the growth of UACC3199 xenograft tumors appeared only to be 
retarded during AG014699 therapy, we next evaluated a prolonged AG014699 
schedule. In this study, 40 mice were implanted with UACC3199 cells and randomly 
assigned to receive: saline (10 mL/kg), AG014699 (10 mg/kg) daily for 5 days of a 7-
day cycle for six cycles, or carboplatin (75 mg/kg) single dose on day 1. Because of 
the variable lag time for the appearance of the tumors observed in the previous 
experiment, mice were randomly assigned to the different treatment groups and 
treatment was initiated on day 42 after implantation when nine mice had confirmed 
tumors (ie, when there were sufficient mice for at least two mice per treatment 
group). In this study, tumor growth was more consistent (Supplementary Figure 2, 
available online) with additional mice randomly assigned to the treatment groups as 
their tumors appeared. The mean time to RTV5 in saline-treated control mice was 
25.2 days (95% CI = 14.0 to 36.0). In AG014699-treated mice, the time to RTV5 was 
extended to 35.8 days (95% CI = 25.0 to 46.0), representing a 10.6-day tumor growth 
delay over un-treated controls (P = .05). For the carboplatin-treated mice, the time to 
RTV5 was 35.7 days (95% CI = 26.0 to 44.0), representing a 10.5-day tumor growth 
delay (P = .02) (Figure 4A and Table 2). Treatment with AG014699 appeared to be 
non-toxic to these mice, with the maximum weight loss among treated mice being 
6.6% compared with a maximum weight loss of 3% in control mice; however, 
carboplatin caused marginal toxicity, with the maximum weight loss being 9.6%.  
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BRCA1-mutated MDA-MB-436 xenograft tumors. MDA-MB-436 cells 
formed xenograft tumors poorly; only 15 of 50 mice that were implanted with these 
cells developed tumors. Treatment of these 15 MDA-MB-436 tumor-bearing mice 
began 44 days after implantation. Because the AG014699 schedule of a once daily 
dose of 10 mg/kg for 5 days of a 7-day cycle for six cycles resulted in greater tumor 
growth delay in the UACC3199 xenografts, we compared this schedule with a single 
dose of carboplatin and a matched saline control in mice bearing MDA-MB-436 
xenograft tumors. Tumors in untreated control mice reached RTV4 after 19 days 
(95% CI = 9.4 to 25.0). Tumor growth was delayed in mice treated with AG014699 (P 
= .03), with a mean time to RTV4 of 29 days (95% CI = 13.0 to 45.0), which was 
equivalent to a tumor growth delay of 10 days (Figure 4B and Table 2). Among this 
group, one mouse had a transient complete tumor regression (ie, no tumor 
detectable) between days 15 and 17. MDA-MB-436 tumors were very sensitive to 
carboplatin treatment, with transient complete tumor regressions observed in two 
mice (one on days 17-50 and the other on days 20-34) and with a third mouse 
experiencing a sustained, durable complete tumor regression from day 15 until it was 
killed at the end of the study. Times to RTV4 in the remaining two mice with tumors 
were 57 and 63 days. AG014699 was also non-toxic in this study, with the maximum 
weight loss among treated mice being 4% and that among control mice being 6.4%; 
however, carboplatin caused measurable toxicity, with the maximum weight loss 
being 13%.  
 
BRCA2-mutated CAPAN-1 xenograft tumors.  All 40 CD-1 nude mice 
implanted with CAPAN-1 cells developed tumors. At 15 days after implantation, mice 
were randomly assigned to the following treatment groups: Saline control (10 mL/kg) 
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daily for 10 days, AG014699 (10 mg/kg) once a day for 10 days, AG014699 (10 
mg/kg) once daily for 5 days of a 7-day cycle for six cycles, a single dose of 
carboplatin (75 mg/kg) on day 1, a combination of carboplatin (75 mg/kg) on day 1 in 
combination with AG014699 (10 mg/kg) once a day for 10 days, or a combination of 
carboplatin (75 mg/kg) on day 1 with AG014699 (10 mg/kg) once a day for 5 days of 
a 7-day cycle for six cycles  
Tumors in untreated mice reached mean RTV4 at 11.5 days (95% CI = 4.0 to 
20.0) (Figure 4C, Table 2, and Supplementary figure 4 available online) consistent 
with previous reports (33). A single dose of carboplatin (on day 1) resulted in one 
complete tumor regression and an increase in mean time to RTV4 of 18 days (95% 
CI = 1.0 to 35.0) (P = .026) compared with that of un-treated control mice. Treatment 
with AG014699 for 10 days resulted in an increase in time to RTV4 of 24 days (95% 
CI = 7.0 to 44.8).  (P = .016), which was equivalent to a 12.5–day growth delay 
(Figure 4C and Table 2). The regimen of AG014699 (10 mg/kg) once daily for 5 days 
of a 7-day cycle for six cycles resulted in a 27.5–day growth delay (ie, time to RTV4 
of 39 days (95% CI = 27.0 to 50.0) (P = .016) compared with control mice (Figure 4C 
and Table 2). The combination of carboplatin and the 10-day AG014699 schedule 
resulted in two complete tumor regressions (one at day 28 and the other at day 35) 
with a tumor growth delay of 27.5 days (time to RTV4 = 39 days; 95% CI = 22.8 to 
55.4) that was greater than either treatment alone (Figure 4B and Table 2). The 
combination of carboplatin with AG014699 given once daily at a dose of 10 mg/kg for 
5 days of a 7-day cycle for six cycles was the most effective treatment, with two 
complete regressions (one at day 7 and the other at day 12) and a tumor growth 
delay of 36.5 days (mean time to RTV4 = 48 days; 95% CI = 10.9 to 86.3) in the 
remaining tumors (Figure 4C and Table 2), which was greater than that achieved with 
carboplatin alone (P = .014). None of the treatments caused statistically significant 
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toxicity (P = 0.08), with maximum body weight loss being less than 5% in all groups, 
except for mice receiving the carboplatin and AG014699 combination schedule 
described above, in which the maximum weight loss was 6.3%.  
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DISCUSSION  
 
The most important data to emerge from this study were from the 
epigenetically silenced BRCA1 UACC3199 model. Cytotoxicity of AG014699 was 
similar in the epigenetically silenced BRCA1 UACC3199 cells and in BRCA1/2 or 
XRCC3 mutated cells (CAPAN-1, IRS-1SF, and MDA-MB-436). AG014699 inhibited 
the growth of UACC3199 xenograft tumors as well as or better than carboplatin.  
One limitation of this study to consider is that we did not authenticate, by 
fingerprinting, the cell lines used. However, cells were obtained from their originators 
or from reputable suppliers, they were isolated from each other by use of medium 
and reagents exclusive to each cell line, and only low-passage numbers of cells were 
used for experiments. Moreover, their behavior (eg, ability or not to form RAD51 foci) 
was consistent with their reported genotypes. The UACC3199 cells were confirmed 
to have methylated BRCA1, and their defect in HRR was confirmed by the 
observation that prolonged exposure to AG014699 failed to induce an increase in 
RAD51 foci.  
We have also shown, to our knowledge, for the first time that PARP inhibition 
is selectively toxic to human cancer cell lines with mutated BRCA1 and 2 and that 
xenograft tumors derived from these cell lines also responded to PARP inhibitors 
therapy. These results support those previously published showing selective 
sensitivity to PARP inhibitors in non-cancer, non-human BRCA1/2-deficient models 
(4, 5) and contrast with previous studies that failed to show such sensitivity in human 
cancer models (17, 18). We also show that other defects in HRR (eg, through 
XRCC3 mutation) confer sensitivity to AG014699, indicating that, in addition to 
BRCA1/2-associated cancers, PARP inhibitors may have therapeutic potential in 
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tumors with other defects in HRR.  The antitumor activity clearly indicates that drug 
levels sufficient to suppress PARP activity and tumor cell viability can be achieved 
with non-toxic doses of AG014699; doses that result in peak plasma concentrations 
of 3.3-5.6 μM and up to 95% PARP inhibition in other tumor models (Huw D. 
Thomas, unpublished data). These data compare favorably with the peak plasma 
concentrations of 2.6 μM (837 ng/mL) and tumor PARP inhibition of 95% that have 
been reported after administration of AG014699 at 18 mg/m2 to patients (28), the 
dose being used in the current phase II AG014699 BRCA study (34), as well as the 
level of PARP inhibition observed in the cell lines described in this study. 
The growth delay caused by the 10-day AG014699 schedule was at least 
equivalent to that after carboplatin treatment of CAPAN-1 xenograft tumors. A greater 
response was observed with more prolonged (once daily for 5 days of a 7-day cycle 
for six cycles) AG014699 therapy. Similarly, we observed a greater response in the 
UACC3199 xenograft model when treated on the prolonged schedule. These results 
indicate that continuous PARP inhibitor therapy might result in a superior clinical 
response than intermittent schedules such as that used for chemosensitization in the 
previous phase I AG014699 trial (days 1-5, every 28 days) (28). Cultured MDA-MB-
436 cells were the most sensitive human cancer cell line to AG014699-induced 
cytotoxicity and also had fewer RAD51 foci in response to AG014699, suggesting 
these cells had the most profound HRR defect. Xenograft tumors derived from these 
cells responded well to AG014699, with one transient complete tumor regression, 
and were also highly sensitive to carboplatin, with two transient and one durable 
complete responses, consistent with a severely HRR- defective phenotype. Similar 
studies, in mice bearing BRCA1- and p53-deleted transplanted mouse mammary 
tumors (35) and in mice bearing autochthonous BRCA2- and p53-deleted mouse 
mammary tumors (36), showed that the PARP inhibitor, AZD2281, on a 28- or 100-
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day cycle, increased survival but was less effective than cisplatin at 6 mg/kg or 
carboplatin at 100 mg/kg, a dose similar to that used in this study. In the 
transplantable, but not the autochthonous, mouse tumor studies, the combination of 
cisplatin and a PARP inhibitor resulted in prolonged recurrence-free and overall 
survival, compared with mice treated with either drug alone. We also found that the 
combination of carboplatin and AG014699 in human pancreatic cancer cells carrying 
a BRCA2 mutation was more effective than either drug alone, resulting in complete 
tumor regressions in two of the five tumors treated.  
These data have demonstrated that AG014699 inhibited growth in BRCA2 
mutated (CAPAN-1), BRCA1 mutated (MDA-MB-436), and BRCA1 epigenetically 
silenced (UACC3199) tumors, with the prolonged AG014699 treatment schedule and 
carboplatin combination being the most effective. However, in interpreting data from 
these xenograft studies, it should be noted that a statistically significant difference 
between treatment groups (determined by P < .05) could have been observed by 
chance, given the multiple statistical comparisons of the different treatment groups. 
The lack of adjustment for multiple statistical comparisons could be considered a 
limitation of the study.  
Encouragingly, we did not observe any toxicity with AG014699 monotherapy 
in these xenograft studies and observed only marginally increased weight loss with 
the combination treatment of AG014699 and carboplatin. Preliminary phase II clinical 
data with the PARP inhibitor, BSI-201, support the increased response and lack of 
toxicity of the combination of PARP inhibitors plus carboplatin among patients with 
triple-negative breast cancer (37), and a phase III study of this combination is 
ongoing.  
Recent reports (38-40) have demonstrated that sensitivity to PARP inhibitors 
can be lost by a secondary intragenic deletion of the original truncating mutation in 
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BRCA1 or BRCA2 that restores an open reading frame and reverses the BRCA1/2 
defect. It is possible that the inherent genomic instability associated with loss of 
BRCA1/2 function could give rise to such spontaneous reversions, which may 
account for the PARP inhibitor resistance seen in the CAPAN-1 cell lines (18). 
Indeed, it seems likely that spontaneous reversion of BRCA2 mutations in CAPAN-1 
cells may be common, because single strand break repair dysfunction from reduced 
ligase III activity has been reported, which would severely compromise the viability of 
a homologous recombination dysfunctional cell (41).   
We found that AG014699 treatment caused increased gH2AX foci formation 
in all cells studied but caused increased RAD51 foci formation only cells with 
functional homologous recombination. These results support the proposed 
mechanism of selective AG014699 toxicity (Figure 5), in which inhibition of PARP-1 
leads to failure of single-strand break repair, which then leads to a double-strand 
break and gH2AX focus formation. In HRR competent, BRCA1/2-proficient cells, 
these double-strand breaks will eventually be repaired by error-free HRR, 
accompanied by RAD51 focus formation, without deleterious effects; however, in 
HRR-deficient cells, repair does not occur resulting in the accumulation of double-
strand breaks and cell death.  
Concerns about potential toxicity in normal tissue of patients receiving PARP 
inhibitors is not un-founded on the basis of our observation that a 24-hour exposure 
to 10 μM AG014669 induces a level of DNA double-strand breaks that is similar to 
that caused by 2 Gy of irradiation. However, it is encouraging that we found no 
increase in cytotoxicity in BRCA1/2 heterozygous cell lines after short-term 
AG014699 exposure and no decrease in survival of BRCA2 heterozygous mice after 
long-term AG014699 treatment that was equivalent to approximately 10 times the 
maximum tolerated patient dose in the phase I trial (28).  The finding of multiple liver 
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tumors in one of the heterozygous mice was not unexpected because sporadic tumor 
formation in mice of that age is not uncommon (42). In addition, the phase I–II clinical 
trials of AG014699 in combination with temozolomide in cancer patients with non-
mutated BRCA1/2 did not report any single-agent AG014699 toxicity (28). However, 
dose-limiting toxicities of myelosuppression and central nervous system side effects 
were observed in the phase I trial of the PARP inhibitor olaparib (previously AZD2281 
or KU-0059436) in patients with advanced solid tumors with a population enriched for 
BRCA1/2 mutation carriers (43).  
Clinical trials of PARP inhibitors are ongoing in BRCA1/2-mutated cancers 
(34). The first to report was the pivotal phase I study of the oral PARP inhibitor, 
olaparib, in which a confirmed partial response rate of 39% (nine of the 23 patients) 
was observed (43). After this initial report (43), phase II studies of olaparib in 
BRCA1/2-associated breast and ovarian cancer have reported objective response 
rates in the 400-mg twice daily dosing cohorts of 33% (11 of the 33 patients) in 
ovarian cancer patients (44) and  41% (11 of the 27 patients) in breast cancer 
patients (45). With different modes of administration, scheduling, specificity, and 
potency of PARP inhibition, it may be that not all PARP inhibitors are equal and it will 
be interesting to see if the response observed with olaparib can be validated with 
other PARP inhibitors. Further studies will hopefully address the many unanswered 
questions about the safety and efficacy of PARP inhibitors in this patient population. 
In summary, we have reported, to our knowledge, the first efficacy results of a 
PARP inhibitor in both in vitro and in vivo models of human cancer that is associated 
with epigenetically silenced BRCA1 as well as mutated BRCA1/2. Antitumor activity 
was observed at non-toxic doses of AG014699 monotherapy, and the combination of 
AG014699 with carboplatin resulted in 40% complete tumor regression and 
prolonged tumor growth delay without statistically significant toxicity. Furthermore, 
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AG014699 was not toxic to BRCA2 heterozygous mice. Our data demonstrating the 
superiority of a more continuous AG014699 dosing schedule (5 days per week for 6 
weeks) in comparison to a 10-day schedule has implications for the clinical 
scheduling of PARP inhibitor monotherapy. Encouragingly, although the mechanisms 
of PARP inhibitors and carboplatin cytotoxicity and resistance somewhat overlap, 
combination therapy with the two drugs was particularly effective in human BRCA1/2-
defective xenograft tumors, which provide robust preclinical support to the conduct of 
clinical trials of combination therapy with carboplatin and PARP inhibitors. The most 
important and, to our knowledge,  novel observation—that epigenetically silenced 
BRCA1 also confers sensitivity to PARP inhibitors monotherapy in vitro and in vivo—
indicates that screening for BRCA1/2 mutations will only identify a subset of patients 
who may respond to PARP inhibitors monotherapy and that PARP inhibitors may 
have a broader therapeutic potential. These data provide robust evidence to support 
the use of PARP inhibitors in the treatment of both sporadic and hereditary BRCA1/2-
related cancers. How to identify which tumors will respond to treatment with PARP 
inhibitors is the next challenge.  
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Table 1: Cell survival after a 24-hour exposure to AG014699*  
Cell line BRCA1/2 or HRR status Mean LC50 for 
AG014699, µM (95% CI)  
Functional HRR 
MCF7 Wild type* 20.2 (14.6 to 25.8) 
MDA-MB-231 BRCA1 hemizygous wild type 21.9 (17.8 to 26.1) 
OSEC1 BRCA2 heterozgote (4630insA in 
exon 11) 
44.8 (9.3 to 80.3) 
OSEC2 Wild type 31.6 (4.1 to 59.1) 
AA8 Wild type 50.7 (33.7 to 67.8) 
Defective HRR 
MDA-MB-436 BRCA1 mutation 5396 + 1G>A 1.3 (-0.12 to 2.8) 
Capan-1 BRCA2 mutation 6174delT 5.5 (2.4 to 8.7) 
UACC3199 BRCA1 silenced by methylation 7.6 (6.1 to 9.1) 
IRS-1SF XRCC3 deficient 1.4 (0.4 to 2.4) 
* Wild type = non-mutated BRCA1 and/or BRCA2; LC50 = dose that results in 
death of 50% of cell population; CI = confidence interval; HRR = homologous 
recombination DNA repair. 
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Figure legends 
 
Figure 1. Cytotoxicity and growth inhibition by AG014699. A) Clonogenic 
survival. Cells were treated with AG014699 at various concentrations, as indicated, 
for 24 hours and survival was determined with the clonogenic assay. Open symbols 
and dashed lines = cells with epigenetically silenced (UACC3199) or mutated BRCA1 
(MDA-MB-436) or with BRCA2 (CAPAN-1) or XRCC3 (IRS-1SF) mutations; solid 
symbols and lines = cells with non-mutated BRCA1/2 (MCF7, OSEC2, AA8) or cells 
that are BRCA1 and/or BRCA2 (BRCA1/2) heterozygous (OSEC1, MDA-MB-231). B) 
Cell proliferation. Cells were treated with AG014699 at various concentrations, as 
indicated, for 6 days. Cell proliferation was assessed by a sulforhodamine B assay. 
Open symbols and dashed lines = BRCA1-mutated HCC1937 cells; solid symbols 
and lines = BRCA1-reconstituted HCC1937-BRC1 or MDA-MB-231 cells. Data in 
both panels are the mean values from three independent experiments, with triplicate 
values for each concentration. Error bars = 95% confidence intervals.  
 
Figure 2. Induction and repair of DNA double-strand breaks after exposure to 
AG014699. A) DNA double-strand breaks. These breaks were assessed by the 
phosphorylated histone H2AX (gH2AX) focus formation assay in cells that were 
exposed to 10 μM AG014699 for 24 hours (filled bars) or 2 Gy of irradiation (open 
bars). Data for all cell lines are shown: the epigenetically silenced (UACC3199), 
mutated BRCA1 (MDA-MB-436, HCC1937), BRCA2 mutated (CAPAN-1) or XRCC3 
mutated (IRS-1SF), non-mutated BRCA1 and/or BRCA2 (BRCA1/2) (MCF7, OSEC2, 
AA8, HCC1937-BRCA1), and the BRCA1/2 heterozygote (OSEC1, MDA-MB-231). 
Data are expressed as the mean percentage of gH2AX foci compared with 
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corresponding untreated control cells. Error bars = 95% confidence intervals (CIs). 
Three independent experiments were performed with triplicate samples for each 
point. B) Homologous recombination repair. This activity was assessed by the 
RAD51 focus formation assay in cells exposed to 10 µM AG014699 for 24 hours. 
Open bars = data for the epigenetically silenced (UACC3199), mutated BRCA1 
(MDA-MB-436, HCC1937), BRCA2 mutated (CAPAN-1), and XRCC3 mutated (IRS-
1SF); filled bars = data for the non-mutated BRCA1/2 (MCF7, OSEC2, AA8, 
HCC1937-BRCA1) and the BRCA1/2 heterozygote (OSEC1, MDA-MB-231). Data 
are the mean percentage of RAD51 foci compared with the corresponding untreated 
control cells. Error bars = 95% CIs. Three independent experiments were performed 
with triplicate samples for each point. P values for statistically significant differences 
between AG014699-treated and untreated control cells are shown. All statistical tests 
were two-sided.  
 
Figure 3. Assessment of AG014699 toxicity in BRCA2 heterozygous 
mice and non-mutated BRCA2 mice. The mouse strain used was 
129/C57BL6/DBA. We randomly assigned mice with non-mutated BRCA2 or BRCA2 
heterozygous mice to the following treatment groups: seven control saline-treated 
mice with non-mutated BRCA2 (black solid line), seven mice with non-mutated 
BRCA2 that were treated with AG014699 (black dashed lines), 10 control saline-
treated BRCA2 heterozygous mice (grey solid line), and 10 BRCA2 heterozygous 
mice that were treated with AG014699 (grey dashed line). A) Mean body weight. The 
weight of each mouse was measured daily during the six-cycle dosing period and 
three times per week at all other times. B) Kaplan-Meier survival curves. There was 
no statistically significant difference between the survival of the four treatment groups 
(logrank test, P = .97). All statistical tests were two-sided.  
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Figure 4. Efficacy of AG014699 treatment in mice bearing BRCA1/2-defective 
xenografts. The efficacy of AG014699 in two different dosing schedules was 
evaluated in comparison to carboplatin therapy in mice bearing UACC3199 (BRCA1 
methylated), MDA-MB-436 (BRCA1 mutated), and CAPAN-1 (BRCA2 mutated) 
xenografts by determining the mean relative tumor volume. There were five mice per 
group in all experiments. Mean RTV data are given (results for individual mice are 
given in Supplementary Figures 2-4, available online). A) UACC3199. i) Experiment 
1. Solid circles and line = saline vehicle alone; open circles and solid line = 
AG014699 (25 mg/kg per day for 10 days); or solid triangles and dashed line = 
carboplatin (single dose of 75 mg/kg on day 1). ii) Experiment 2. Solid circles and 
line = saline vehicle alone; open circles and solid line = AG014699 (10 mg/kg, day 1-
5 on a 7-day cycle for six cycles); solid triangles and dashed line = carboplatin (75 
mg/kg, single dose on day 1); arrow = final day of treatment. B) MDA-MB-436. Solid 
circles and line = saline vehicle alone; open circles and solid line = AG014699 (10 
mg/kg day 1-5 on a 7-day cycle for six cycles); or solid triangles and dashed line = 
carboplatin (75 mg/kg,single dose on day 1). C) CAPAN-1. i) Experiment 1. Solid 
circles and line = saline vehicle alone; open circles and solid line = AG014699 (10 
mg/kg daily for 10 day), solid triangles and dashed line = carboplatin (75 mg/kg 
intraperitoneally); open triangles and dashed line = combination of carboplatin and 
AG014699 (10 mg/kg daily for 10 day). ii) Experiment 2. Solid circles and line = 
saline vehicle alone; open circles and solid line= AG014699 (10 mg/kg, day 1-5 on a 
7-day cycle for six cycles); solid triangles and dashed line = carboplatin (75 mg/kg, 
single dose on day 1); open triangles and dashed line = combination of carboplatin 
and AG014699 (10 mg/kg, day 1-5 on a 7-day cycle for six cycles).  
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Figure 5. Model for the selective toxicity mechanism of poly(ADP-ribose) 
polymerase (PARP) inhibitors in cancers with defective BRCA1 and/or BRCA2 
(BRCA1/2). Tumors may arise in carriers of a heterozygous mutation in either 
BRCA1 or BRCA2 through loss or mutation of the second allele or in unaffected 
individuals by spontaneous loss and/or mutation of both alleles of BRCA1 or BRCA2. 
Inhibition of PARP-1 leads to failure of single-strand break repair. When a single-
strand break is encountered by a DNA replication fork, the fork stalls and/or a double-
strand break (DSB) occurs, which is represented by an increase in the formation of 
gH2AX foci. In homologous recombination (HR) competent, BRCA1/2-proficient 
normal cells or BRCA1/2 heterozygous cells, these DSBs will be repaired by error-
free HR, as represented by RAD51 foci, which will allow the cell to survive. In HR-
deficient cells, repair does not occur, resulting in DSB accumulation and cell death. 
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Supplementary Figure legends 
 
Supplementary Figure 1. Inhibition of poly(ADP-ribose) polymerase (PARP) 
activity in cells by 10 µM AG014699. Open bars = data for the epigenetically 
silenced (UACC3199), mutated BRCA1 (MDA-MB-436, HCC1937), BRCA2 mutated 
(CAPAN-1) or XRCC3  mutated (IRS-1SF); filled bars = data for the non-mutated 
BRCA1 and/or BRCA2 (BRCA1/2) (MCF7, OSEC2, AA8, HCC1937-BRCA1) and the 
BRCA1/2 heterozygote (OSEC1, MDA-MB-231). Data are mean percentage of PARP 
inhibition relative to untreated control cells. Three independent experiments were 
preformed with two replicate samples per point. Error bars = 95% confidence 
intervals.  
 
Supplementary Figure 2. UACC3199 xenograft tumor growth in CD-1 nude 
mice. Tumor growth, calculated as the relative tumor volume (RTV) after each 
treatment, is shown as a function of time from the start of treatment. In each panel, 
all data from one treatment are shown with the same symbol and correspond to the 
symbols used for the mean data given in Figure 4A. Panels A–C show data from 
experiment 1 (mean data are shown in Figure 4Ai), and panels D–F show data from 
experiment 2 (mean data are shown in Figure 4Aii). A) Vehicle control (saline daily 
for 10 days). B) AG014699 (25 mg/kg daily for 10 days). C) Carboplatin (single dose 
at 75 mg/kg on day 1). D) Vehicle control (saline, daily for days 1-5 of a 7-day cycle 
for six cycles). E) AG014699 (10 mg/kg daily for days 1-5 of a 7-day cycle for six 
cycles). F) Carboplatin (single dose at 75 mg/kg on day 1)  
Supplementary Figure 3. MDA-MB-436 xenograft tumor growth in CD-1 nude 
mice. Tumor growth, calculated as the relative tumor volume (RTV) after each 
treatment, is shown as a function of time from the start of treatment. In each panel, 
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all data from one treatment are shown with the same symbol, corresponding to the 
symbols used for the mean data in Figure 4B. A) Vehicle control (saline daily for days 
1-5 of a 7-day cycle for six cycles). B) AG014699 (10 mg/kg daily on days 1-5 of a 7-
day cycle for six cycles). C) Carboplatin (single dose at 75 mg/kg day 1).  
 
Supplementary Figure 4. CAPAN-1 xenograft tumor growth in CD-1 nude mice. 
Tumor growth, calculated as the relative tumor volume (RTV) after each treatment, is 
shown as a function of time from the start of treatment. In each panel, all data from 
one treatment are shown with the same symbol, corresponding to the symbols used 
for the mean data in Figure 4C. A) Vehicle control (saline daily for 10 days). B) 
AG014699 (10 mg/kg daily for 10 days). C) AG014699 (10 mg/kg daily for days 1-5 
of a 7-day cycle for six cycles). D) Carboplatin (single dose of 75 mg/kg on day 1). E) 
Combination therapy with carboplatin (single dose of 75 mg/kg on day 1) plus 
AG014699 (10 mg/kg daily for 10 days). F) Combination therapy with carboplatin 
(single dose of 75 mg/kg on day 1) plus AG014699 (10 mg/kg daily on days 1-5 of a 
7-day cycle for six cycles).  
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